Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2019

Open Access 01-12-2019 | Panniculitis | Case report

Multifocal pleomorphic dermal sarcoma and the role of inflammation and immunosuppression in a lung transplant patient: a case report

Authors: Mary E. Anderson, Nemanja Rodic, Antonio Subtil, Dawn Queen, Selim Arcasoy, George W. Niedt, Peter W. Heald, Larisa J. Geskin

Published in: Journal of Medical Case Reports | Issue 1/2019

Login to get access

Abstract

Background

Pleomorphic dermal sarcoma is the cutaneous variant of undifferentiated pleomorphic sarcoma. It is a rare malignancy of unclear histogenesis; it is a diagnosis of exclusion that requires extensive use of immunohistochemistry to rule out other malignancies. Pleomorphic dermal sarcoma typically presents as a solitary tumor in sun-exposed areas and may have unpredictable clinical behavior, with some tumors associated with metastasis and death.

Case presentation

We present an unusual case of multifocal pleomorphic dermal sarcoma arising in the areas of alpha-1-antitrypsin deficiency panniculitis in a lung transplant patient. Our patient was a 58-year-old white woman whose initial presentation was consistent with alpha-1-antitrypsin deficiency panniculitis. She then developed extensive multifocal, bleeding, and ulcerated nodules in the areas of the panniculitis. A skin biopsy was consistent with a diagnosis of pleomorphic dermal sarcoma. Her immunosuppressive regimen was decreased, and she was treated with liposomal doxorubicin 40 mg/m2 every 3 weeks with some initial improvement in the size of her tumors. However, soon after beginning therapy, she developed pneumonia and septic shock and ultimately died from multi-organ failure.

Conclusions

We hypothesize that chronic, multifocal inflammation in the skin in the setting of immunosuppression led to simultaneous, malignant transformation in numerous skin lesions. We discuss the challenges of diagnosing pleomorphic dermal sarcoma, therapeutic options, and stress the need for multidisciplinary management of these cases.
Literature
1.
go back to reference Al-Agha OM, Igbokwe AA. Malignant fibrous histiocytoma: between the past and the present. Arch Pathol Lab Med. 2008;132(6):1030–5.PubMed Al-Agha OM, Igbokwe AA. Malignant fibrous histiocytoma: between the past and the present. Arch Pathol Lab Med. 2008;132(6):1030–5.PubMed
2.
go back to reference Tardio JC, Pinedo F, Aramburo JAA, et al. Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated. J Cutan Pathol. 2016;43:101–12.CrossRef Tardio JC, Pinedo F, Aramburo JAA, et al. Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated. J Cutan Pathol. 2016;43:101–12.CrossRef
3.
go back to reference Radons J. The role of inflammation in sarcoma. Adv Exp Med Biol. 2014;816:259–313.CrossRef Radons J. The role of inflammation in sarcoma. Adv Exp Med Biol. 2014;816:259–313.CrossRef
4.
go back to reference Abdul Hassan Tawbi H, Burgess M, Crowley J, Van Tine BA, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue sarcomas: results of SARC028 – a multicenter phase II study. J Clin Oncol. 2016;34(15 suppl):11006.CrossRef Abdul Hassan Tawbi H, Burgess M, Crowley J, Van Tine BA, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue sarcomas: results of SARC028 – a multicenter phase II study. J Clin Oncol. 2016;34(15 suppl):11006.CrossRef
5.
go back to reference Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–23.CrossRef Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–23.CrossRef
6.
go back to reference Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37:870–7.CrossRef Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37:870–7.CrossRef
7.
go back to reference Fletcher CDM. Pleomorphic malignant fibrous histiocytoma: fact or fiction? Am J Surg Pathol. 1992;16:213–28.CrossRef Fletcher CDM. Pleomorphic malignant fibrous histiocytoma: fact or fiction? Am J Surg Pathol. 1992;16:213–28.CrossRef
8.
go back to reference Ozzello L, Stout AP, Murray MR. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer. 1963;16:331–4.CrossRef Ozzello L, Stout AP, Murray MR. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer. 1963;16:331–4.CrossRef
9.
go back to reference Fletcher CDM, Unni K, Mertens F. World Health Organization classification of tumors: pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2002. p. 1–415. Fletcher CDM, Unni K, Mertens F. World Health Organization classification of tumors: pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2002. p. 1–415.
10.
go back to reference McCalmont TH. Correction and clarification regarding AFX and pleomorphic dermal sarcoma. J Cutan Pathol. 2012;39:8.CrossRef McCalmont TH. Correction and clarification regarding AFX and pleomorphic dermal sarcoma. J Cutan Pathol. 2012;39:8.CrossRef
11.
go back to reference Miller K, Goodlaad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histological features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol. 2012;36:1317–26.CrossRef Miller K, Goodlaad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histological features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol. 2012;36:1317–26.CrossRef
12.
go back to reference Hafner J, Kunzi W, Weinreich T. Malignant fibrous histiocytoma and atypical fibroxanthoma in renal transplant recipients. Dermatology. 1999;198:29–32.CrossRef Hafner J, Kunzi W, Weinreich T. Malignant fibrous histiocytoma and atypical fibroxanthoma in renal transplant recipients. Dermatology. 1999;198:29–32.CrossRef
13.
go back to reference McCoppin HH, Christiansen D, Stasko T, et al. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience. Am J Dermatol Surg. 2011;38:230–9.CrossRef McCoppin HH, Christiansen D, Stasko T, et al. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience. Am J Dermatol Surg. 2011;38:230–9.CrossRef
14.
go back to reference Grivvenikov SI, Greten FR, Karin M. Immunity, infection, and cancer. Cell. 2010;140:883–99.CrossRef Grivvenikov SI, Greten FR, Karin M. Immunity, infection, and cancer. Cell. 2010;140:883–99.CrossRef
15.
go back to reference Foster AD, et al. The aging immune system and its relationship with cancer. Aging Health. 2011;7(5):707–18.CrossRef Foster AD, et al. The aging immune system and its relationship with cancer. Aging Health. 2011;7(5):707–18.CrossRef
16.
go back to reference Hoki Y, Hiraku Y, Ma N, et al. iNOS-dependent DNA damage in patients with malignant fibrous histiocytoma in relation to prognosis. Cancer Sci. 2007;98:163–8.CrossRef Hoki Y, Hiraku Y, Ma N, et al. iNOS-dependent DNA damage in patients with malignant fibrous histiocytoma in relation to prognosis. Cancer Sci. 2007;98:163–8.CrossRef
17.
go back to reference Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 2004;5:182–90.CrossRef Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol. 2004;5:182–90.CrossRef
18.
go back to reference Kanterman J, et al. New insights into chronic inflammation induced immunosuppression. Semin Cancer Biol. 2012;22(4):307–18.CrossRef Kanterman J, et al. New insights into chronic inflammation induced immunosuppression. Semin Cancer Biol. 2012;22(4):307–18.CrossRef
19.
go back to reference Ziemer M. Atypical fibroxanthoma. J Dtsch Dermatol Ges. 2012;10:537–48.PubMed Ziemer M. Atypical fibroxanthoma. J Dtsch Dermatol Ges. 2012;10:537–48.PubMed
20.
go back to reference Henderson SA, Torres-Cabala CA, Curry JL, et al. p40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies. Am J Surg Pathol. 2014;38:1102–10.CrossRef Henderson SA, Torres-Cabala CA, Curry JL, et al. p40 is more specific than p63 for the distinction of atypical fibroxanthoma from other cutaneous spindle cell malignancies. Am J Surg Pathol. 2014;38:1102–10.CrossRef
21.
go back to reference Kalinova L, Majek O, Stehlik D, Krejci K, Bachleda P. Skin cancer incidence in renal transplant recipients - a single center study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154:257–60.CrossRef Kalinova L, Majek O, Stehlik D, Krejci K, Bachleda P. Skin cancer incidence in renal transplant recipients - a single center study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154:257–60.CrossRef
22.
go back to reference Brewer JD, Shanafelt TD, Call TG, Cerhan JR, Roenigk RK, Weaver AL, Otley CC. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia. Int J Dermatol. 2015;54(8):e287–93.CrossRef Brewer JD, Shanafelt TD, Call TG, Cerhan JR, Roenigk RK, Weaver AL, Otley CC. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia. Int J Dermatol. 2015;54(8):e287–93.CrossRef
23.
go back to reference Nascimento AF, Raut CP. Diagnosis and management of pleomorphic sarcomas (so-called “MFH”) in adults. J Surg Oncol. 2008;97:330–9.CrossRef Nascimento AF, Raut CP. Diagnosis and management of pleomorphic sarcomas (so-called “MFH”) in adults. J Surg Oncol. 2008;97:330–9.CrossRef
24.
go back to reference Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016;122:2952–60.CrossRef Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. 2016;122:2952–60.CrossRef
25.
go back to reference Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft tissue sarcoma: an open label phase 1b and randomized phase 2 trial. Lancet. 2016;388:488–97.CrossRef Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft tissue sarcoma: an open label phase 1b and randomized phase 2 trial. Lancet. 2016;388:488–97.CrossRef
Metadata
Title
Multifocal pleomorphic dermal sarcoma and the role of inflammation and immunosuppression in a lung transplant patient: a case report
Authors
Mary E. Anderson
Nemanja Rodic
Antonio Subtil
Dawn Queen
Selim Arcasoy
George W. Niedt
Peter W. Heald
Larisa J. Geskin
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2019
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-019-2093-9

Other articles of this Issue 1/2019

Journal of Medical Case Reports 1/2019 Go to the issue